STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $54,242 | -61.6% | 13,767 | +3.7% | 0.00% | -100.0% |
Q2 2023 | $141,135 | +56.4% | 13,277 | +22.6% | 0.00% | 0.0% |
Q1 2023 | $90,239 | -7.9% | 10,833 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $97,995 | -28.5% | 10,617 | -0.4% | 0.00% | 0.0% |
Q3 2022 | $137,000 | -1.4% | 10,656 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $139,000 | -30.2% | 10,506 | +10.9% | 0.00% | 0.0% |
Q1 2022 | $199,000 | -18.1% | 9,477 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $243,000 | -8.6% | 10,144 | -2.9% | 0.00% | 0.0% |
Q3 2021 | $266,000 | -26.1% | 10,448 | -2.3% | 0.00% | 0.0% |
Q2 2021 | $360,000 | +17.3% | 10,696 | +35.3% | 0.00% | 0.0% |
Q1 2021 | $307,000 | -31.3% | 7,906 | +9.6% | 0.00% | -50.0% |
Q4 2020 | $447,000 | +82.4% | 7,212 | -1.3% | 0.00% | +100.0% |
Q3 2020 | $245,000 | +37.6% | 7,305 | -2.2% | 0.00% | 0.0% |
Q2 2020 | $178,000 | -22.9% | 7,471 | -25.8% | 0.00% | 0.0% |
Q1 2020 | $231,000 | +42.6% | 10,069 | +75.7% | 0.00% | 0.0% |
Q4 2019 | $162,000 | +30.6% | 5,732 | -0.8% | 0.00% | 0.0% |
Q3 2019 | $124,000 | – | 5,780 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |